Aldeyra Therapeutics (NASDAQ:ALDX – Get Free Report) posted its earnings results on Thursday. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.05, FiscalAI reports.
Aldeyra Therapeutics Stock Down 4.9%
Shares of ALDX stock traded down $0.03 during trading on Thursday, hitting $0.62. The company had a trading volume of 862,145 shares, compared to its average volume of 1,019,323. The stock’s 50-day moving average is $1.07 and its two-hundred day moving average is $2.23. Aldeyra Therapeutics has a 52 week low of $0.53 and a 52 week high of $5.93.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on ALDX shares. Wall Street Zen lowered shares of Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. BTIG Research reiterated a “buy” rating on shares of Aldeyra Therapeutics in a research report on Tuesday, September 29th. Weiss Ratings lowered Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, September 14th. Finally, HC Wainwright restated a “neutral” rating and set a $2.00 target price on shares of Aldeyra Therapeutics in a research report on Wednesday, September 30th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $5.50.
Get Our Latest Stock Report on ALDX
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for immune-mediated diseases. The company’s research centers on reactive aldehyde species, or RASP, which are inflammatory signaling molecules that may contribute to ocular and systemic diseases.
Aldeyra’s lead investigational product is reproxalap, an eye drop designed to inhibit RASP activity. The company has studied reproxalap in conditions including dry eye disease and allergic conjunctivitis.
Further Reading
- Five stocks we like better than Aldeyra Therapeutics
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
